Trial site
Hematology Oncology of Indiana
Indianapolis, Indiana 46260, United StatesNot linked to an institution yet
- 7running trials
- 1closed trial
The trials here
What the 8 trials at this site are about, from their registry records.
- Phase
- Phase 37 trials
- Phase 21 trial
- Status
- Recruiting5 trials
- Active, not recruiting1 trial
- Completed1 trial
- Not yet recruiting1 trial
- Lead sponsor
- Nurix Therapeutics, Inc.2 trials
- Amgen1 trial
- Astellas Pharma Global Development, Inc.1 trial
- Eli Lilly and Company1 trial
- ImmunityBio, Inc.1 trial
- and 2 more
Running trials
Recruiting
Study of NX-5948 Versus Pirtobrutinib in R/R CLL/SLL
NCT07516093· Phase 3· Nurix Therapeutics, Inc.· Source
Recruiting
A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer
NCT07284849· Phase 3· Incyte Corporation· Source
Recruiting
A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer
NCT07409272· Phase 3· Astellas Pharma Global Development, Inc.· Source
Contact: Astellas Pharma Global Development, Inc.
Recruiting
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
NCT07174336· Phase 3· Eli Lilly and Company· Source
Contact: Ruemu Birhiray (principal investigator)
Recruiting
A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
NCT07221500· Phase 2· Nurix Therapeutics, Inc.· Source
Recruiting
Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint Inhibitor Therapy
NCT06745908· Phase 3· ImmunityBio, Inc.· Source
Contact: Robin Wilson
Active, not recruiting
A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)
NCT07005128· Phase 3· Amgen· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error